A Peculiar Case of Priapism: The Hypercoagulable State in Patients with Severe COVID-19 Infection

  • Germain Lam General Internal Medicine, Withybush General Hospital, Haverfordwest, Pembrokeshire, United Kingdom
  • Rowan Mccarthy General Internal Medicine, Withybush General Hospital, Haverfordwest, Pembrokeshire, United Kingdom
  • Rana Haider General Internal Medicine, Withybush General Hospital, Haverfordwest, Pembrokeshire, United Kingdom

Keywords

Priapism, thromboembolism, coagulopathy, COVID-19 infection, anticoagulation

Abstract

It is increasingly recognised that patients with severe COVID-19 infection have a significant risk of thromboembolic events. We describe a patient who rapidly deteriorated due to severe infection with COVID-19, and developed priapism in the last days of his life. We believe development of priapism may be associated with a prothrombotic state secondary to COVID-19 infection. This case report supports the widely reported increased incidence of thrombosis in patients with severe COVID-19 infection.

VIEW THE ENTIRE ARTICLE

References

  • Cannegieter SC, Klok FA. COVID-19 associated coagulopathy and thromboembolic disease: commentary on an interim expert guidance. Res Pract Thromb Haemost 2020;4(4):439–445.

  • Wang T, Chen R, Liu C, Liang W, Guan W, Tang R, et al. Attention should be paid to venous thromboembolism prophylaxis in the management of COVID-19. Lancet Haematol 2020;7(5):e362–363.

  • Llitjos JF, Leclerc M, Chochois C, Monsallier JM, Ramakers M, Auvray M, et al. High incidence of venous thromboembolic events in anticoagulated severe COVID-19 patients. J Thromb Haemost 2020 Apr 22. doi: 10.1111/jth.14869 [Epub ahead of print].

  • Middeldorp S, Coppens M, van Haaps TF, Foppen M, Vlaar AP, Müller MCA, et al. Incidence of venous thromboembolism in hospitalized patients with COVID-19. J Thromb Haemost 2020 May 5. doi: 10.1111/jth.14888 [Epub ahead of print].

  • Bikdeli B, Madhavan MV, Jimenez D, Chuich T, Dreyfus I, Driggin E, et al. COVID-19 and thrombotic or thromboembolic disease: implications for prevention, antithrombotic therapy, and follow-up. J Am Coll Cardiol 2020;75(23):2950–2973.

  • Kollias A, Kyriakoulis KG, Dimakakos E, Poulakou G, Stergiou GS, Syrigos K. Thromboembolic risk and anticoagulant therapy in COVID?19 patients: emerging evidence and call for action.Br J Haematol 2020;189(5):846–847.

  • Poggiali E, Bastoni D, Ioannilli E, Vercelli A, Magnacavallo A. Deep vein thrombosis and pulmonary embolism: two complications of COVID-19 pneumonia? Eur J Case Rep Intern Med 2020;7(5):001646.

  • Levey HR, Segal RL, Bivalacqua TJ. Management of priapism: an update for clinicians. Ther Adv Urol 2014;6(6):230–244.

  • Montague DK, Jarow J, Broderick GA, Dmochowski RR, Heaton JPW, Lue TF, et al. American Urological Association guideline on the management of priapism. J Urol 2003;170(4 Pt 1):1318–1324.

  • Van der Horst C, Stuebinger H, Seif C, Melchior D, Martínez-Portillo FJ, Juenemann KP. Priapism: etiology, pathophysiology and management. Int Braz J Urol 2003;29(5):391–400
  • Published: 2020-07-14

    Issue: Vol 7 No 8 (view)

    Section: Articles

    How to cite:
    1.
    Lam G, Mccarthy R, Haider R. A Peculiar Case of Priapism: The Hypercoagulable State in Patients with Severe COVID-19 Infection. EJCRIM 2020;7 doi:10.12890/2020_001779.